The Investor’s Insider:
Protecting Against Securities Fraud

Posts Tagged ‘Pharmaceuticals’

Stoll Berne Investigates Galena Biopharma

Posted on: February 20th, 2014 by Nadine Gartner

Our firm is investigating potential claims concerning whether Galena Biopharma, Inc. (“Galena”) (NASDAQ: GALE), its board of directors and/or officers violated state or federal securities laws, or breached fiduciary duties owed to shareholders. Read more…

Judge Grants Class Certification Over False Claims by Radient Pharmaceuticals

Posted on: December 4th, 2012 by Nadine Gartner

A federal judge in the Central District of California has certified a class of investors in a pending securities fraud lawsuit against Radient Pharmaceuticals. Read more…

Pfizer Settles Class Action Lawsuit by Former Wyeth Shareholders

Posted on: November 15th, 2012 by Keith Dubanevich

Pfizer Inc. (“Pfizer”), the world’s largest pharmaceutical company, has agreed to pay $67.5 million to settle a class action lawsuit by shareholders of the former Wyeth Inc. (“Wyeth”), a pharmaceutical company bought by Pfizer in 2009.  Read more…

Legal Disclaimer

The information contained in this blog does not constitute legal advice, and does not create an attorney-client relationship. We make no claims, promises or guarantees about the accuracy, completeness, or adequacy of the information contained in or linked to this blog.

About this blog

The purpose of this blog is to provide information to the general public and to practitioners about developments that may impact Oregon investors.

About the author

  • Nadine Gartner

  • Keith Dubanevich
  • Nadine Gartner’s practice focuses on complex business litigation and class actions. Prior to becoming a lawyer, Nadine worked as an investment banking analyst.
Follow stollberne on Twitter

Subscribe to this blog